Inion Oyj - Company Announcement

Inion promotes Christian Johnson to Sales Director responsible for markets outside the USA

Inion Oy
(“Inion or the “Company”)

Inion promotes Christian Johnson to Sales Director responsible for markets
outside the USA 

Tampere, Finland and Guildford, UK. 15 January 2009, Inion (LSE: IIN.L), a
company focused on the development and commercialisation of novel biodegradable
medical implants, is pleased to announce the promotion of Christian Johnson to
the position of Sales Director for key markets outside the USA. He will report
to David Follows, Inion's Chief Operating Officer. 

Christian is a sales and marketing professional with 11 years of experience
gained initially in the pharmaceutical industry and later in the medical
devices industry. Most recently, he spent seven successful years at Johnson &
Johnson working in a number of sales and marketing roles of increasing
responsibility within its Spine Implant Business Unit (part of J&J's DePuy
operating company). During this time, he gained valuable experience in
launching and marketing innovative new products, such as a pedicle screw system
for spine fusion, which quickly became DePuy's number one brand. Christian also
demonstrated excellent leadership qualities and recruited and developed a new
team that contributed significantly to the overall success of DePuy's UK
business. 

Since joining Inion in 2007, Christian has made a significant contribution
within the Marketing Team in supporting the refocus and prioritization of the
Company's portfolio of innovative biodegradable medical implants for spine and
speciality orthopaedic applications. 

Chris Lee, Inion's CEO, said, “Christian's passion for Inion's product
portfolio, support of the aims and ambitions of our organisation and his desire
for success make him the ideal choice to take on this demanding role. Inion is
focused on establishing a well-organised and profitable international sales and
marketing operation and we are confident that Christian has the necessary
qualities to build this important part of our business. We congratulate him on
this well-deserved promotion.” 

-ends-

For further information, please contact:

Inion Oy 
Chris Lee, Chief Executive Officer
Julien Cotta, Chief Financial Officer
Tel: +44 (0)1483 685390

Citigate Dewe Rogerson
Mark Swallow / Helena Galilee / David Dible	
Tel: +44 (0)207 638 9571

About Inion (www.inion.com)

Inion Oy is a medical devices company focused on the development and successful
commercialisation of innovative and unique biodegradable and bioactive surgical
implants in selected high value orthopaedic market segments. 

Inion's core expertise and technology lies in the design and manufacture of
innovative biodegradable plates, screws, pins and membranes, which are used to
enhance the healing of bone or soft tissue injuries to the skeleton, such as
those caused by trauma or by reconstructive surgery. Inion implants are made
from its proprietary Inion family of biomaterials, with properties tailored for
specific surgical applications, in terms of strength, flexibility and rate of
degradation 
 
Inion is also focused on developing proprietary new bioactive and biodegradable
biomaterials that promote bone healing and accelerate patient rehabilitation. 

Inion was incorporated in early 2000 and listed on the Official List of the UK
Listing Authority in December 2004 (ticker: IIN). The Company has offices in
the UK and US, and its head office, R&D and production facilities are in
Tampere, Finland. 

This announcement includes "forward-looking statements" which include all
statements other than statements of historical facts, including, without
limitation, those regarding the Group's financial position, business strategy,
plans and objectives of management for future operations (including development
plans and objectives relating to the Group's products), and any statements
preceded by, followed by or that include forward-looking terminology such as
the words "targets", "believes", "estimates", "expects", "aims", "intends",
"will", "can", "may", "anticipates", "would", "should", "could" or similar
expressions or the negative thereof. Such forward-looking statements involve
known and unknown risks, uncertainties and other important factors beyond the
Group's control that could cause the actual results, performance or
achievements of the Group to be materially different from future results,
performance or achievements expressed or implied by such forward-looking
statements. Such forward-looking statements are based on numerous assumptions
regarding the Group's present and future business strategies and the
environment in which the Group will operate in the future. Among the important
factors that could cause the Group's actual results, performance or
achievements to differ materially from those in forward-looking statements
include those relating to Inion's funding requirements, regulatory approvals,
reliance on third parties, intellectual property, key personnel and other
factors. These forward-looking statements speak only as at the date of this
announcement. The Group expressly disclaims any obligation or undertaking to
disseminate any updates or revisions to any forward-looking statements
contained in this announcement to reflect any change in the Group's
expectations with regard thereto or any change in events, conditions or
circumstances on which any such statements are based. As a result of these
factors, prospective investors are cautioned not to rely on any forward-looking
statement.